Interferon-stimulated neutrophils as a predictor of immunotherapy response.

ABSTRACT: Despite the remarkable success of anti-cancer immunotherapy, its effectiveness remains confined to a subset of patients-emphasizing the importance of predictive biomarkers in clinical decision-making and further mechanistic understanding of treatment response. Current biomarkers, however, lack the power required to accurately stratify patients. Here, we identify interferon-stimulated, Ly6E^hi neutrophils as a blood-borne biomarker of anti-PD1 response in mice at baseline. Ly6E^hi neutrophils are induced by tumor-intrinsic activation of the STING (stimulator of interferon genes) signaling pathway and possess the ability to directly sensitize otherwise non-responsive tumors to anti-PD1 therapy, in part through IL12b-dependent activation of cytotoxic T cells. By translatin

SUBMITTER: Benguigui M 

PROVIDER: S-EPMC10864002 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature